Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome
DOI:10.7326/M19-0291
Category: What we’re reading
WHAT WE’RE READING – JOURNAL CLUB
Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation
DOI: 10.1056/NEJMoa1817083
Causes and Risk Factors of Cerebral Ischemic Events in Patients With Atrial Fibrillation Treated With Non–Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention: The RENo Study
DOI: 10.1161/STROKEAHA.119.025350
WHAT WE’RE READING – JOURNAL CLUB
Intensive Blood-Pressure Lowering in Patients with Acute Cerebral Hemorrhage
DOI: 10.1056/NEJMoa1603460
Blood pressure control and clinical outcomes in acute intracerebral haemorrhage: a preplanned pooled analysis of individual participant data.
DOI: 10.1016/S1474-4422(19)30196-6
Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trial.
DOI: 10.1016/S1474-4422(08)70069-3
Rapid Blood-Pressure Lowering in Patients with Acute Intracerebral Hemorrhage
DOI: 10.1056/NEJMoa1214609
WHAT WE’RE READING – JOURNAL CLUB
Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke
DOI: 10.1056/NEJMoa1705915
Closure or Medical Therapy for Cryptogenic Stroke with Patent Foramen Ovale
DOI: 10.1056/NEJMoa1009639
Percutaneous Closure of Patent Foramen Ovale in Cryptogenic Embolism
DOI: 10.1056/NEJMoa1211716
Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke
DOI: 10.1056/NEJMoa1707404
Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke
DOI: 10.1056/NEJMoa1301440
Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke
DOI: 10.1056/NEJMoa1610057
What We’re Reading – Journal Club
Blood Pressure and Outcome After Mechanical Thrombectomy With Successful Revascularization
doi.org/10.1161/STROKEAHA.118.024687
WHAT WE’RE READING – JOURNAL CLUB
Effect of Standard vs Intensive Blood Pressure Control on the Risk of Recurrent Stroke
A Randomized Clinical Trial and Meta-analysis
DOI:10.1001/jamaneurol.2019.2167
WHAT WE’RE READING – JOURNAL CLUB
Efficacy and safety of endovascular thrombectomy in mild ischemic stroke: results from a retrospective study and meta-analysis of previous trials
doi.org/10.1186/s12883-019-1372-9
Mechanical Thrombectomy for Minor and Mild Stroke Patients Harboring Large Vessel Occlusion in the Anterior Circulation
https://doi.org/10.1161/STROKEAHA.117.018113
Stroke. 2017;48:3274–3281
Endovascular Thrombectomy for Mild Strokes: How Low Should We Go?
doi.org/10.1161/STROKEAHA.118.022114
Stroke. 2018;49:2398–2405
Mechanical Thrombectomy in Patients With Milder Strokes and Large Vessel Occlusions
doi.org/10.1161/STROKEAHA.118.021106
Stroke. 2018;49:2391–2397
WHAT WE’RE READING – JOURNAL CLUB
Clopidogrel Plus Aspirin Versus Warfarin in Patients With Stroke and Aortic Arch Plaques
DOI:10.1161 STROKEAHA.113.004251
Warfarin and Aspirin in Patients with Heart Failure and Sinus Rhythm
DOI: 10.1056/NEJMoa1202299
Comparison of Warfarin and Aspirin for Symptomatic Intracranial Arterial Stenosis
DOI: 10.1056/NEJMoa043033
Stenting versus Aggressive Medical Therapy for Intracranial Arterial Stenosis
DOI: 10.1056/NEJMoa1105335
WHAT WE’RE READING – JOURNAL CLUB
Clopidogrel Plus Aspirin Versus Warfarin in Patients With Stroke and Aortic Arch Plaques
https://doi.org/10.1161/STROKEAHA.113.004251
Apixaban versus Warfarin in Patients with Atrial Fibrillation
DOI: 10.1056/NEJMoa1107039
Oral Anticoagulants vs Aspirin in Nonvalvular Atrial Fibrillation
An Individual Patient Meta-analysis
DOI:10.1001/jama.288.19.2441
Dabigatran versus Warfarin in Patients with Atrial Fibrillation
DOI: 10.1056/NEJMoa0905561
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
DOI: 10.1056/NEJMoa1009638
Warfarin and Aspirin in Patients with Heart Failure and Sinus Rhythm
DOI: 10.1056/NEJMoa1202299
What We’re Reading – Journal Club
ATLANTIS Trial
Results for Patients Treated Within 3 Hours of Stroke Onset
DOI: 10.1161 AHA Stroke. 2002;33:493–496
Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke
N Engl J Med 2008; 359:1317-1329
DOI: 10.1056/NEJMoa0804656
The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6h of acute ischemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial
https://doi.org/10.1016/S0140-6736(12)60768-5
TISSUE PLASMINOGEN ACTIVATOR FOR ACUTE ISCHEMIC STROKE
THE NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE rt-PA STROKE STUDY GROUP
DOI: 10.1056/NEJM199512143332401
